| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Research Support, Non-U.S. Gov't; Editorial; Comment
- Language: English
- [Hepatology] 2023 Aug 01; Vol. 78 (2), pp. 385-387. <i>Date of Electronic Publication: </i>2023 Apr 15.
- MeSH Terms: Antiviral Agents* / pharmacology ; Antiviral Agents* / therapeutic use ; Hepatitis C* / drug therapy ; Humans ; Mutation, Missense ; Hepacivirus / genetics
- Comments: Comment on: Hepatology. 2023 Aug 1;78(2):607-620. (PMID: 36999537) ; Comment on: Hepatology. 2023 Aug 1;78(2):621-636. (PMID: 36999539)
- References: Sarrazin C. Treatment failure with DAA therapy: importance of resistance. J Hepatol. 2021;74:1472–1482. ; Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE, et al. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol. 2010;84:5277–5293. ; Fernandez-Antunez C, Wang K, Fahnoe U, Mikkelsen LS, Gottwein JM, Bukh J, et al. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system. Hepatology. 2023;78:621–636. ; Howe AYM, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, et al. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Rep. 2022;4:100462. ; Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, et al. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol. 2021;74:801–810. ; Dietz J, Mullhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, et al. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure. J Hepatol. 2023;78:57–66. ; Vo-Quang E, Soulier A, Ndebi M, Rodriguez C, Chevaliez S, Leroy V, et al. Virological characterization of treatment failures and retreatment outcomes in patients infected with “unusual” HCV genotype 1 subtypes. Hepatology. 2023;78:607–620. ; Childs K, Davis C, Cannon M, Montague S, Filipe A, Tong L, et al. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. J Hepatol. 2019;71:1099–1105. ; Gupta N, Mbituyumuremyi A, Kabahizi J, Ntaganda F, Muvunyi CM, Shumbusho F, et al. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. Lancet Gastroenterol Hepatol. 2019;4:119–126.
- Substance Nomenclature: 0 (Antiviral Agents)
- Entry Date(s): Date Created: 20230413 Date Completed: 20230719 Latest Revision: 20230902
- Update Code: 20231215
|
